Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIKISJRQD)
  Drug Name Metoclopramide Drug Info Amisulpride Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antiemetics Antipsychotic Agents
  Structure

 Mechanism of Metoclopramide-Amisulpride Interaction (Severity Level: Major)
     Additive antidopaminergic effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Metoclopramide Amisulpride
      Mechanism Extrapyramidal effects Extrapyramidal effects
      Key Mechanism Factor 1
Factor Name Antidopaminergic effects
Factor Description Antidopamines are medications that inhibit or block the neurotransmitter activity of dopamine or related substances. Dopamine deficiency is associated with Parkinson's disease, restless legs syndrome and depression, and low dopamine levels can make you feel tired, moody, unmotivated and many other symptoms.
      Mechanism Description
  • Additive antidopaminergic effects by the combination of Metoclopramide and Amisulpride 

Recommended Action
      Management Due to the potential for increased risk of serious and potentially irreversible extrapyramidal reactions, metoclopramide should not be prescribed in combination with other antidopaminergic agents. In addition, metoclopramide should not be used for longer than 12 weeks except in rare cases where therapeutic benefit is anticipated to outweigh the risk of developing tardive dyskinesia.

References
1 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
2 Cerner Multum, Inc. "Australian Product Information.".
3 Ganzini L, Casey DE, Hoffman WF, McCall AL "The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders." Arch Intern Med 153 (1993): 1469-75. [PMID: 8512437]
4 Grimes JD "Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy." N Engl J Med 305 (1981): 1417. [PMID: 7300862]
5 JimenezJimenez FJ, GarciaRuiz PJ, Molina JA "Drug-induced movement disorders." Drug Saf 16 (1997): 180-204. [PMID: 9098656]
6 Kenney C, Hunter C, Davidson A, Jankovic J "Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia." J Clin Pharmacol (2008):. [PMID: 18223146]
7 Lata PF, Pigarelli DL "Chronic metoclopramide therapy for diabetic gastroparesis." Ann Pharmacother 37 (2003): 122-6. [PMID: 12503946]
8 Lavy S, Melamed E, Penchas S "Tardive dyskinesia associated with metoclopramide." Br Med J 1 (1978): 77-8. [PMID: 620205]
9 Matson JL, Mayville EA, Bielecki J, Smalls Y, Eckholdt CS "Tardive dyskinesia associated with metoclopramide in persons with developmental disabilities." Res Dev Disabil 23 (2002): 224-33. [PMID: 12102590]
10 Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
11 Putnam PE, Orenstein SR, Wessel HB, Stowe RM "Tardive dyskinesia associated with use of metoclopramide in a child." J Pediatr 121 (1992): 983-5. [PMID: 1447672]
12 Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV "Metoclopramide and tardive dyskinesia." Biol Psychiatry 36 (1994): 630-2. [PMID: 7833431]
13 Skidmore F, Reich SG "Tardive Dystonia." Curr Treat Options Neurol 7 (2005): 231-236. [PMID: 15814076]
14 Srinivasan K, Mouli KS, Viegas B, Khan MF, Vas M "Metoclopramide induced tardive dyskinesia." J Indian Med Assoc 89 (1991): 260-1. [PMID: 1795112]
15 Stewart RB, Cerda JJ, Moore MT, Hale WE "Metoclopramide: an analysis of inappropriate long-term use in the elderly." Ann Pharmacother 26 (1992): 977-9. [PMID: 1504411]